CR20230553A - Regímenes de dosificación expandidos para inhibidores de integrina - Google Patents

Regímenes de dosificación expandidos para inhibidores de integrina

Info

Publication number
CR20230553A
CR20230553A CR20230553A CR20230553A CR20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A
Authority
CR
Costa Rica
Prior art keywords
sup
regímenes
expandidos
dosificación
inhibidores
Prior art date
Application number
CR20230553A
Other languages
English (en)
Inventor
Eric Lefebvre
Scott Turner
Martin Decaris
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CR20230553A publication Critical patent/CR20230553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a formas de dosificación para la administración diaria de compuestos de fórmula (A) y fórmula (I): (A) (I) o una sal de estos, donde R1 , R2 , R10, R11, R12, R13, R14, R15, R16, q y p son tal como se describen en la presente. Los compuestos de fórmula (A), fórmula (I) y composiciones farmacéuticas de estos son inhibidores de integrina ανβ6 que son útiles para el tratamiento de fibrosis, tal como la fibrosis pulmonar idiopática (IFF) y la neumonía intersticial inespecífica (NSIP).
CR20230553A 2021-04-30 2022-04-29 Regímenes de dosificación expandidos para inhibidores de integrina CR20230553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182757P 2021-04-30 2021-04-30
PCT/US2022/072013 WO2022232838A1 (en) 2021-04-30 2022-04-29 Expanded dosage regimens for integrin inhibitors

Publications (1)

Publication Number Publication Date
CR20230553A true CR20230553A (es) 2024-04-01

Family

ID=83848780

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230553A CR20230553A (es) 2021-04-30 2022-04-29 Regímenes de dosificación expandidos para inhibidores de integrina

Country Status (14)

Country Link
US (1) US20230028658A1 (es)
EP (1) EP4329755A4 (es)
JP (1) JP2024517765A (es)
KR (1) KR20240024060A (es)
CN (1) CN117615760A (es)
AU (1) AU2022265730A1 (es)
CA (1) CA3173787A1 (es)
CL (1) CL2023003219A1 (es)
CO (1) CO2023016295A2 (es)
CR (1) CR20230553A (es)
IL (1) IL308063A (es)
MX (1) MX2023012794A (es)
TW (1) TW202308637A (es)
WO (1) WO2022232838A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
CR20230262A (es) 2020-11-19 2023-07-26 Pliant Therapeutics Inc Inhibidor de integrina y usos de este
TW202535400A (zh) 2023-12-14 2025-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984394T3 (es) * 2016-11-08 2024-10-29 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v
KR20240167712A (ko) * 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
LT3761980T (lt) * 2018-03-07 2024-03-12 Pliant Therapeutics, Inc. Aminorūgščių junginiai ir jų panaudojimo būdai
US11419869B2 (en) * 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
EP4416147A1 (en) * 2021-10-14 2024-08-21 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents

Also Published As

Publication number Publication date
MX2023012794A (es) 2023-12-15
EP4329755A1 (en) 2024-03-06
CA3173787A1 (en) 2022-11-03
JP2024517765A (ja) 2024-04-23
WO2022232838A1 (en) 2022-11-03
KR20240024060A (ko) 2024-02-23
CL2023003219A1 (es) 2024-05-31
TW202308637A (zh) 2023-03-01
AU2022265730A1 (en) 2023-11-16
EP4329755A4 (en) 2025-03-19
CN117615760A (zh) 2024-02-27
US20230028658A1 (en) 2023-01-26
CO2023016295A2 (es) 2023-12-11
IL308063A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
EP4509512A3 (en) Amino acid compounds and methods of use
MX2023012794A (es) Regímenes de dosificación expandidos para inhibidores de integrina.
CR20210041A (es) Compuestos de aminoácidos con ligadores no ramificados y métodos de uso
CR20210224A (es) Compuestos de amoniácidos y métodos de uso
ZA202209563B (en) Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
MX2022013753A (es) Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
MX2024004438A (es) Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes.
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
PH12023552774A1 (en) Nek7 inhibitors
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
WO2024155965A3 (en) Biomarkers for use in integrin inhibitor therapy
JOP20240171A1 (ar) مركبات يوراسيل بها استبدال بـ n3 على هيئة مثبطات trpa1
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
MX2025007577A (es) Inhibidores de la integrina alfa-v-beta-8 y sus usos
EA202190452A1 (ru) Ингибиторы cdk8/19
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.
GEAP202416376A (en) Tetrahydrothieno pyridine derivatives as ddrs inhibitors
MX2025006787A (es) Inhibidores de fosfoglicerato deshidrogenasa para el tratamiento de fibrosis
MX2024000620A (es) Derivados de sulfamoilbenceno y sus usos.
EA202092110A1 (ru) Аминокислотные соединения и способы применения
SA521422311B1 (ar) صور بلورية لمثبط مستقبل المنشط من البروتياز-4
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor